What is Raymond James's price target for EXAS?

Raymond James's latest stated price target for Exact Sciences Corporation (EXAS) is $90, from its action on Feb 23, 2022.

What is Raymond James's rating on EXAS?

Raymond James rates EXAS Mkt Perform, a neutral rating, as of Jan 18, 2023.

When did Raymond James last change its view on EXAS?

On Jan 18, 2023, Raymond James downgrades to Mkt Perform from Outperform.

Analyst firms · Raymond James · EXAS

Raymond James EXAS price target and rating history

Exact Sciences Corporation (EXAS) · Health Care

Raymond James rates Exact Sciences Corporation (EXAS) Mkt Perform with a $90 price target, as of its latest action on Jan 18, 2023. It has published 3 rating actions on EXAS since November 2021, including 0 upgrades and 2 downgrades.

Current rating: Mkt Perform
Price target: $90
Median target, all firms: Too few
Actions on EXAS: 3

Raymond James price target on EXAS

Raymond James price target on EXAS, each point a stated target, November 2021 to February 2022.

Every Raymond James rating on EXAS

Jan 18, 2023
DowngradeRaymond James downgrades to Mkt Perform from Outperform
Feb 23, 2022
ReiterateRaymond James cuts its price target to $90 from $130, keeps Outperform
Nov 3, 2021
DowngradeRaymond James downgrades to Outperform from Strong Buy, price target $160 to $130

How other firms rate EXAS

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
Mizuho	Neutral	$105	Jan 20, 2026
Evercore ISI	In-line	$105	Jan 5, 2026

Questions about Raymond James and EXAS

What is Raymond James's price target for EXAS?: Raymond James's latest stated price target for Exact Sciences Corporation (EXAS) is $90, from its action on Feb 23, 2022.
What is Raymond James's rating on EXAS?: Raymond James rates EXAS Mkt Perform, a neutral rating, as of Jan 18, 2023.
When did Raymond James last change its view on EXAS?: On Jan 18, 2023, Raymond James downgrades to Mkt Perform from Outperform.

More EXAS rating histories

All Raymond James ratings EXAS news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.